Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
NBIX Stock Chart & Stats
$152.16
$0.29(0.21%)
At close: 4:00 PM EST
$152.16
$0.29(0.21%)
Day’s Range― - ―
52-Week Range$84.23 - $157.67
Previous CloseN/A
Volume209.65K
Average Volume (3M)1.10M
Market Cap
$15.17B
Enterprise Value$13.75B
Total Cash (Recent Filing)$1.11B
Total Debt (Recent Filing)$428.40M
Price to Earnings (P/E)36.3
Beta0.61
Next Earnings
Feb 11, 2026EPS Estimate
1.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.04
Shares Outstanding99,705,696
10 Day Avg. Volume1,012,143
30 Day Avg. Volume1,095,665
Financial Highlights & Ratios
PEG Ratio1.22
Price to Book (P/B)5.29
Price to Sales (P/S)5.82
P/FCF Ratio24.60
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue5.13
Enterprise Value/Gross Profit5.21
Enterprise Value/Ebitda20.67
Forecast
1Y Price Target
$176.67Price Target Upside16.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
EPS Forecast (FY)5.11
Revenue Forecast (FY)$2.86B
Bulls Say, Bears Say
Bulls Say
Earnings PotentialThe expected share price return is 41.4%.
Pipeline GrowthThe rest of the pipeline, including osavampator, direclidine, and eight other earlier-stage clinical programs, are seen as additional shots-on-goal to build value beyond Ingrezza and Crenessity.
Product PerformanceCrenessity's adoption is tracking ahead of expectations as KOLs prioritize high-severity CAH patients, cite reliable biomarker normalization and emphasize meaningful quality-of-life gains.
Bears Say
Clinical Trial FailureNBI-1070770 did not meet its primary endpoint relative to placebo in a Phase 2 trial for adults with major depressive disorder.
Impact On EarningsRemoving NBI'770 from the earnings model sees the price target fall 2.8% to $173.
Limited MDD OptionsNBI-770 Phase 2 disappointment positions osavampator as the only shot on goal in MDD.
Neurocrine News
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $84.23 and its highest was $157.67 in the past 12 months.
What is Neurocrine’s market cap?
Neurocrine’s market cap is $15.17B.
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Feb 11, 2026 which is in 73 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Oct 28, 2025. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.594 by $0.446.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is 1.86.
How many shares outstanding does Neurocrine have?
Neurocrine has 99,705,696 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $2.04 in its last earnings report, beating expectations of $1.594. Following the earnings report the stock price went down -6.351%.
Which hedge fund is a major shareholder of Neurocrine?
Currently, no hedge funds are holding shares in NBIX
Neurocrine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$176.67 (16.11% Upside)
$176.67 (16.11% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 403.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 13.6%
Last 30 Days ▲ 13.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.19%
12-Months-Change
Fundamentals
Return on Equity
14.96%
Trailing 12-Months
Asset Growth
20.67%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. (NBIX) is a biopharmaceutical company focused on developing innovative therapeutics to treat neurological and endocrine diseases and disorders. Founded in 1992 and headquartered in San Diego, California, the company operates primarily in the biotechnology sector. Neurocrine's core products include Ingrezza (valbenazine) for the treatment of tardive dyskinesia and Ongentys (opicapone) for the treatment of Parkinson's disease. The company is committed to advancing treatments for a range of conditions, including sleep disorders, hormonal disorders, and movement disorders.
NBIX Company Deck
NBIX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and successful product launches, particularly with CRENESSITY and INGREZZA, alongside robust pipeline development. However, there are notable challenges such as the failure of the valbenazine study to meet its primary endpoint and pricing pressures on INGREZZA. Despite these challenges, the overall sentiment reflects confidence in continued growth and strategic investments.View all NBIX earnings summariesNBIX Stock 12 Month Forecast
Average Price Target
$176.67
▲(16.11% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Pacira Pharmaceuticals
―
Teva Pharmaceutical
―
Amphastar Pharmaceuticals
―
Ownership Overview
1.09% Insiders
29.80% Mutual Funds
24.44% Other Institutional Investors
18.05% Public Companies and Individual Investors